Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $82.30 USD
Change Today -0.75 / -0.90%
Volume 820.5K
PCRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:21 PM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (PCRX) Snapshot

Open
$83.20
Previous Close
$83.05
Day High
$84.07
Day Low
$77.88
52 Week High
02/25/15 - $121.95
52 Week Low
04/28/14 - $63.56
Market Cap
3.0B
Average Volume 10 Days
1.0M
EPS TTM
$-0.40
Shares Outstanding
36.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PACIRA PHARMACEUTICALS INC (PCRX)

pacira pharmaceuticals inc (PCRX) Related Bloomberg News

View More Bloomberg News

pacira pharmaceuticals inc (PCRX) Related Businessweek News

No Related Businessweek News Found

pacira pharmaceuticals inc (PCRX) Details

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company’s lead product include, EXPAREL, a liposome injection of bupivacaine, an amide-type anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. It also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. The company’s development pipeline comprises DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical stage for the treatment of acute postsurgical pain; and DepoTranexamic Acid, a pre-clinical phase product for the treatment or prevention of excessive blood loss during surgery by promoting hemostasis. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

445 Employees
Last Reported Date: 02/24/15
Founded in 2006

pacira pharmaceuticals inc (PCRX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Head of Technical Op...
Total Annual Compensation: $534.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $503.2K
Chief Medical Officer
Total Annual Compensation: $407.6K
Principal Accounting Officer and Executive Di...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2014.

pacira pharmaceuticals inc (PCRX) Key Developments

Pacira Pharmaceuticals' Post-Surgical Analgesia Drug Exparel Fails to Secure Expanded Approval by US FDA

Pacira Pharmaceuticals (US) has announced that it has received a complete response letter (CRL) from the US FDA regarding its supplemental New Drug Application filing for Exparel (bupivacaine liposome injectable suspension) as a potential nerve block to provide post-surgical analgesia. The firm has announced that it will schedule a meeting with the Division of Anesthesia, Analgesia and Addiction Products at the FDA's Center for Drug Evaluation and Research to discuss the undisclosed issues that were raised in the CRL.

Pacira Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Pacira Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $61.793 million compared to $33.564 million a year ago. Income from operations was $7.920 million compared to loss from operations of $9.820 million a year ago. Income before income taxes was $5.975 million compared to loss before income taxes of $11.956 million a year ago. Net income was $5.802 million or $0.14 per diluted common share compared to net loss of $11.956 million or $0.36 per basic and diluted common share a year ago. Non-GAAP net income was $14.460 million or $0.35 per basic common share compared to non-GAAP net loss of $7.635 million or $0.23 per basic and diluted common share a year ago. The company announced that as a measure of operating cash flow, it has generated adjusted EBITDA of $18.2 million. Overall cash accumulation in the quarter was offset by $7 million of capital expenditure. For the year, the company reported total revenues of $197.668 million compared to $85.551 million a year ago. Loss from operations was $5.165 million compared to $53.289 million a year ago. Loss before income taxes was $13.543 million compared to $64.351 million a year ago. Net loss was $13.716 million or $0.39 per basic and diluted common share compared to $63.909 million or $1.93 per basic and diluted common share a year ago. Non-GAAP net income was $15.245 million or $0.37 per diluted common share compared to non-GAAP net loss of $45.039 million or $1.36 per basic and diluted common share a year ago. For the year 2015, the company expects EXPAREL revenues of $310 million to $330 million, with approximately 10% of these projected revenues coming from the pending nerve block indication. The company announced that it expects to report excluding stock-based compensation so on a non-GAAP basis, product gross margin of 72% to 75%, R&D expense of $25 million to $30 million. The company expects to be generating substantial EBITDA in 2015. The company expects to incur $35 million of capital expenditure related to manufacturing capacity expansion development along with about $15 million of routine capital expenditure, so these investments will moderate its cash balance accumulation in 2015 from the starting point of $183 million. The company expects its cash taxes to be minimal in 2015 due to the initial application of an NOL balance of approximately $330 million.

Pacira Pharmaceuticals, Inc. to Report Q4, 2014 Results on Feb 24, 2015

Pacira Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Feb 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCRX:US $82.30 USD -0.75

PCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $44.66 USD +1.56
Alkermes PLC $57.54 USD -0.61
Cumberland Pharmaceuticals Inc $6.90 USD +0.29
Durect Corp $1.98 USD -0.095
Halyard Health Inc $47.62 USD -0.01
View Industry Companies
 

Industry Analysis

PCRX

Industry Average

Valuation PCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.5x
Price/Book 18.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit www.pacira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.